Develops drug candidates for patients with inflammatory and immune-related diseases, including vitiligo, allergic contact dermatitis and acute respiratory distress syndrome.
10-K for FY2025, filed Dec 12, 2025We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to…View ↗
In Medical Dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune…View ↗
Our most advanced Respiratory drug candidate is EB05 (paridiprubart). Paridiprubart represents a new class of emerging therapies called…View ↗
The company has no customers for its investigational medicines. If a candidate is approved, it plans to sell through its own sales force or use outside sales and marketing, licensing, collaboration or distribution partners.
10-K for FY2025, filed Dec 12, 2025Because we are focused on the discovery and development of drugs, we do not have any marketing or distribution capabilities, nor are we at…View ↗
10-Q for Q3 FY2026, filed Aug 13, 2026
−$5.4MView ↗
8-K, filed Nov 9, 2026
On November 8, 2026, Edesa Biotech, Inc., together with its wholly owned subsidiaries (the “Company”), entered into a Collaboration and…View ↗
Program focus
The latest report describes a pulmonary fibrosis program under evaluation; the older report described development for systemic sclerosis.
10-K for FY2022, filed Dec 16, 2022 10-K for FY2025, filed Dec 12, 2025In addition to EB05, we are developing product candidates for a number of chronic dermatological and inflammatory conditions. We recently…View ↗
We are seeking to advance additional product candidates as well as add new disease indications for current product candidates, and from…View ↗
Loading...